Clearside Biomedical is at the sale-approval stage of its Chapter 11 case, with the debtor pressing to close a two-part asset monetization by June 30 while keeping a July 1 confirmation hearing on the calendar. The case began with a voluntary Delaware Chapter 11 filing on November 23, 2025, after the biopharmaceutical debtor faced a shrinking cash runway, sustained losses, Nasdaq compliance pressure, and unsuccessful financing efforts; its first-day declaration described a company with no funded debt, roughly $3.0 million of unencumbered cash, and a strategy built around an expedited section 363 sale of its ophthalmology assets and royalty-related rights First Day DeclarationDkt. 2.
The debtor’s restructuring path has since centered on selling the operating and intellectual-property platform rather than reorganizing around the existing public-company business. Clearside designated Health Ocean Pharma (Eye) Limited as successful bidder for certain remaining assets, including the equity interests in Clearside Royalty LLC, CLS-AX and Axitinib-related rights, data, and 154 assigned contracts, for $4.0 million plus assumed liabilities and a capped 2.5% royalty stream; the revised sale order also preserves HCR’s first-priority security interest in the Clearside Royalty equity and waives the usual stay periods to permit closing by June 30 Revised Health Ocean Sale Order CertificationDkt. 391. The debtor also served sale materials reflecting that the Health Ocean bid, together with the separate Excess Royalties sale and a Steel Partners plan sponsor transaction bid, was selected as the value-maximizing package for the estate .
The near-term posture is a sequence of sale and plan milestones. The June 9 sale agenda says the Health Ocean sale is going forward only if the court has questions, with objections resolved, while the equity committee motion has been adjourned under the approved equity settlement framework Amended Sale Hearing AgendaDkt. 392. For the Excess Royalties, Aura Biosciences declined to proceed and backup bidder Healthcare Royalty Partners IV, L.P. was designated successful bidder at a $6.0 million cash purchase price, with a June 16 sale hearing and June 30 outside closing date HCR Excess Royalties Sale NoticeDkt. 386. The court also scheduled the June 16 omnibus hearing, leaving the case’s immediate path focused on completing the royalty sale, closing the Health Ocean transaction, and moving toward the scheduled July 1 confirmation hearing Omnibus Hearing OrderDkt. 387.